1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads to difficulty with balance, movement, vision, speech and swallowing. Symptoms include fatigue, headaches, dizziness, depression, Parkinsonism, behavioral, cognitive, and gait disturbances that cause imbalance and arthralgias. The only proven risk factor for progressive supranuclear palsy is age. Treatment includes anticholinergic medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 13 and 4 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Progressive Supranuclear Palsy - Overview
- Progressive Supranuclear Palsy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Progressive Supranuclear Palsy - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development
- Allyx Therapeutics Inc
- Alterity Therapeutics Ltd
- AlzProtect SAS
- Anhorn Medicines Co Ltd
- Aprinoia Therapeutics Inc
- Arvinas Inc
- Asahi Kasei Pharma Corp
- Asceneuron SA
- AZTherapies Inc
- Cortice Biosciences Inc
- Merck & Co Inc
- NeuroTau Inc
- New Amsterdam Sciences Inc
- Novartis AG
- Pinteon Therapeutics Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- Reata Pharmaceuticals Inc
- Retrotope Inc
- TauC3 Biologics Ltd
- TauRx Therapeutics Ltd
- Transposon Therapeutics Inc
- UCB SA
- Vaxxinity Inc
- Verge Genomics
- Voyager Therapeutics Inc
- Progressive Supranuclear Palsy - Drug Profiles
- AHT-434 - Drug Profile
- Product Description
- Mechanism Of Action
- ALX-002 - Drug Profile
- Product Description
- Mechanism Of Action
- Anti-tau - Drug Profile
- Product Description
- Mechanism Of Action
- Antibodies to Inhibit Tau Protein for Progressive Supranuclear Palsy and Corticobasal Degeneration - Drug Profile
- Product Description
- Mechanism Of Action
- APNmAb-005 - Drug Profile
- Product Description
- Mechanism Of Action
- ASN-120290 - Drug Profile
- Product Description
- Mechanism Of Action
- AZP-2006 - Drug Profile
- Product Description
- Mechanism Of Action
- bepranemab - Drug Profile
- Product Description
- Mechanism Of Action
- censavudine - Drug Profile
- Product Description
- Mechanism Of Action
- deulinoleate ethyl - Drug Profile
- Product Description
- Mechanism Of Action
- fasudil - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Modified Cell Therapy for Progressive Supranuclear Palsy - Drug Profile
- Product Description
- Mechanism Of Action
- hydromethylthionine mesylate - Drug Profile
- Product Description
- Mechanism Of Action
- MK-8719 - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Inhibit tau Protein for Alzhiemer's Disease and Progressive Supranuclear Palsy - Drug Profile
- Product Description
- Mechanism Of Action
- NAS-114 - Drug Profile
- Product Description
- Mechanism Of Action
- NAS-150 - Drug Profile
- Product Description
- Mechanism Of Action
- NIO-752 - Drug Profile
- Product Description
- Mechanism Of Action
- omaveloxolone - Drug Profile
- Product Description
- Mechanism Of Action
- PNT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- PRX-005 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit Tau for Frontotemporal Lobar Dementia (FTLD), Progressive Supranuclear Palsy and Alzheimer's Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Frontotemporal Dementia, Lewy Body Dementia, Progressive Supranuclear Palsy and Schizophrenia - Drug Profile
- Product Description
- Mechanism Of Action
- Tau - Drug Profile
- Product Description
- Mechanism Of Action
- Tau - Drug Profile
- Product Description
- Mechanism Of Action
- Tau Degrader - Drug Profile
- Product Description
- Mechanism Of Action
- Tau Modulator - Drug Profile
- Product Description
- Mechanism Of Action
- TBL-100 - Drug Profile
- Product Description
- Mechanism Of Action
- tolfenamic acid - Drug Profile
- Product Description
- Mechanism Of Action
- TPI-287 - Drug Profile
- Product Description
- Mechanism Of Action
- Various Tauopathies - Drug Profile
- Product Description
- Mechanism Of Action
- Progressive Supranuclear Palsy - Dormant Projects
- Progressive Supranuclear Palsy - Discontinued Products
- Progressive Supranuclear Palsy - Product Development Milestones
- Featured News & Press Releases
- Apr 11, 2022: APRINOIA Therapeutics received FDA clearance to initiate APNmAb005 Phase 1 clinical trial
- Jan 20, 2022: Alzprotect completes recruitment for phase 2a clinical trial for AZP2006 in progressive supranuclear palsy (PSP)
- Nov 19, 2021: Announcement of enrollment of first patient in Phase IIa clinical trial of OBP-601 (Censavudine, TPN-101) in patients with progressive supranuclear palsy (PSP)
- Sep 30, 2021: Asceneuron to provide update on O-GlcNAcase Pipeline at upcoming conferences
- Aug 11, 2021: Retrotope announces completion of enrollment in phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
- Jun 30, 2021: Retrotope announces initiation of phase 2 study of RT001 in patients with progressive supranuclear palsy (PSP)
- May 12, 2021: Voyager Therapeutics presents new preclinical data showing reduction of pathological Tau with Vectorized Anti-Tau antibody
- Feb 18, 2021: Woolsey Pharmaceuticals emerges from stealth mode to announce patients enrolled in two new CNS studies
- Jan 28, 2021: Pinteon Therapeutics announces upcoming scientific presentations
- Sep 14, 2020: Alzprotect forges ahead with first patients enrolled in Phase 2a study in progressive supranuclear palsy (PSP)
- Apr 27, 2020: US FDA allows trial to proceed for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
- Feb 18, 2020: US FDA grants orphan drug designation for Retrotope’s RT001 in the treatment of progressive supraNuclear palsy (PSP)
- Oct 17, 2019: Arvinas to Present update on Small Molecule to Inhibit Microtubule Associated Protein Tau for Alzheimer's Disease and Progressive Supranuclear Palsy at the 2nd Targeted Protein Degradation Summit
- Sep 25, 2019: UCB presents UCB0107 anti-Tau immunotherapy phase I study results at World Movement Disorders Conference
- Sep 18, 2019: Alzprotect gets green light from French Regulator to start phase 2a clinical trial in Progressive Supranuclear Palsy (PSP)
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Progressive Supranuclear Palsy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Progressive Supranuclear Palsy - Pipeline by Allyx Therapeutics Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Alterity Therapeutics Ltd, 2022
- Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, 2022
- Progressive Supranuclear Palsy - Pipeline by Anhorn Medicines Co Ltd, 2022
- Progressive Supranuclear Palsy - Pipeline by Aprinoia Therapeutics Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Arvinas Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Asahi Kasei Pharma Corp, 2022
- Progressive Supranuclear Palsy - Pipeline by Asceneuron SA, 2022
- Progressive Supranuclear Palsy - Pipeline by AZTherapies Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Merck & Co Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by NeuroTau Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by New Amsterdam Sciences Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Novartis AG, 2022
- Progressive Supranuclear Palsy - Pipeline by Pinteon Therapeutics Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by ProMIS Neurosciences Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Prothena Corp Plc, 2022
- Progressive Supranuclear Palsy - Pipeline by Reata Pharmaceuticals Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Retrotope Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by TauC3 Biologics Ltd, 2022
- Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd, 2022
- Progressive Supranuclear Palsy - Pipeline by Transposon Therapeutics Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by UCB SA, 2022
- Progressive Supranuclear Palsy - Pipeline by Vaxxinity Inc, 2022
- Progressive Supranuclear Palsy - Pipeline by Verge Genomics, 2022
- Progressive Supranuclear Palsy - Pipeline by Voyager Therapeutics Inc, 2022
- Progressive Supranuclear Palsy - Dormant Projects, 2022
- Progressive Supranuclear Palsy - Discontinued Products, 2022
- Number of Products under Development for Progressive Supranuclear Palsy, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Allyx Therapeutics Inc
- Alterity Therapeutics Ltd
- AlzProtect SAS
- Anhorn Medicines Co Ltd
- Aprinoia Therapeutics Inc
- Arvinas Inc
- Asahi Kasei Pharma Corp
- Asceneuron SA
- AZTherapies Inc
- Cortice Biosciences Inc
- Merck & Co Inc
- NeuroTau Inc
- New Amsterdam Sciences Inc
- Novartis AG
- Pinteon Therapeutics Inc
- ProMIS Neurosciences Inc
- Prothena Corp Plc
- Reata Pharmaceuticals Inc
- Retrotope Inc
- TauC3 Biologics Ltd
- TauRx Therapeutics Ltd
- Transposon Therapeutics Inc
- UCB SA
- Vaxxinity Inc
- Verge Genomics
- Voyager Therapeutics Inc
